Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.45 |
| ▸ | TNKS | O95271 | 1/20 | 0.45 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.45 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | CETP | P11597 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 4/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6185164 | 1.00 | TNKS2 (0.45) | TNKS2TNKSPARP3DAOCETP | |
| SCHEMBL4871394 | 0.85 | CETP (0.43) | DAOCETPNR1I2SCN5AGRM5 | |
| SCHEMBL4871396 | 0.85 | CETP (0.43) | DAOCETPNR1I2SCN5AGRM5 | |
| SCHEMBL4871404 | 0.85 | CETP (0.43) | DAOCETPNR1I2SCN5AGRM5 | |
| SCHEMBL11099684 | 0.81 | MAPT (0.42) | TNKS2GRM5MAPTALDH1A1 | |
| SCHEMBL9671149 | 0.81 | MAPT (0.42) | TNKS2GRM5MAPTALDH1A1 | |
| SCHEMBL11099686 | 0.81 | MAPT (0.42) | TNKS2GRM5MAPTALDH1A1 | |
| SCHEMBL338191 | 0.80 | GRM5 (0.49) | GRM5 | |
| SCHEMBL6374631 | 0.80 | GRM5 (0.49) | GRM5 | |
| SCHEMBL8192290 | 0.80 | GRM5 (0.49) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361648-B2 | Heterocyclylakylamines as muscarinic receptor antagonists | ROCHE PALO ALTO LLC (US) | 2008-04-22 | — | — | US | disclosed |
| US-20060287293-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | ROCHE PALO ALTO LLC | 2006-12-21 | — | — | US | disclosed |
| US-7094778-B2 | Heterocyclylalkylamines as muscarinic receptor antagonists | SYNTEX (U.S.A.) LLC (US) | 2006-08-22 | — | — | US | disclosed |
| EP-1289965-B1 | SUBSTITUTED 1-AMINOALKYL-LACTAMS AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-10-26 | — | — | EP | disclosed |
| US-20040087581-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | DVORAK CHARLES ALOIS (US) | 2004-05-06 | — | — | US | disclosed |
| US-6667301-B2 | Therapy for muscular disorders, urogenital disorders, gastrointestinal disorders, respiratory system disorders | SYNTEX (U.S.A.) LLC | 2003-12-23 | — | — | US | disclosed |
| EP-1289965-A1 | SUBSTITUTED 1-AMINOALKYL-LACTAMS AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-03-12 | — | — | EP | disclosed |
| US-20020004501-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | SYNTEX (U.S.A.) LLC | 2002-01-10 | — | — | US | disclosed |
| WO-2001090081-A1 | SUBSTITUTED 1-AMINOALKYL-LACTAMS AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287293-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | CHRM5, CHRM2, CHRM3 | TNKS2 4010/4885TNKS 4234/4885PARP3 2831/4885 |
| US-20020004501-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | CHRM5, CHRM2, CHRM1 | TNKS2 4241/4885TNKS 4007/4885PARP3 3007/4885 |
| US-20040087581-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | CHRM5, CHRM2, CHRM1 | TNKS2 4241/4885TNKS 4007/4885PARP3 3007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.